Heron’s HTX-011 meets postoperative pain endpoints

Heron Therapeutics Inc. (NASDAQ:HRTX) gained $5.80 (27%) to $27.30 on Monday after it said HTX-011 met the primary and key secondary endpoints in the Phase III EPOCH1 and EPOCH2 trials to treat postoperative pain. The company reiterated its plan to submit an NDA to FDA next half for the candidate.

HTX-011 is a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam using Heron’s Biochronomer polymer-based drug delivery platform...